| Market Cap | 3B | P/E | 10.96 | EPS this Y | -200.00% | Ern Qtrly Grth | - |
| Income | -132.08M | Forward P/E | 31.45 | EPS next Y | 166.70% | 50D Avg Chg | -7.00% |
| Sales | 278.58M | PEG | 3.50 | EPS past 5Y | -57.25% | 200D Avg Chg | -15.00% |
| Dividend | N/A | Price/Book | 3.02 | EPS next 5Y | -76.72% | 52W High Chg | -57.00% |
| Recommedations | 1.90 | Quick Ratio | 9.03 | Shares Outstanding | 141.55M | 52W Low Chg | 11.00% |
| Insider Own | 1.36% | ROA | -1.47% | Shares Float | 98.26M | Beta | 0.01 |
| Inst Own | 105.51% | ROE | -19.39% | Shares Shorted/Prior | 7.91M/8.44M | Price | 11.95 |
| Gross Margin | 46.73% | Profit Margin | -47.41% | Avg. Volume | 2,999,532 | Target Price | 11.27 |
| Oper. Margin | -14.59% | Earnings Date | Nov 5 | Volume | 6,578,673 | Change | 8.34% |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
| Wells Fargo | Overweight | Aug 27, 24 |
| RBC Capital | Outperform | Aug 16, 24 |
| Morgan Stanley | Equal-Weight | Aug 13, 24 |
| Goldman Sachs | Neutral | Aug 8, 24 |
| UBS | Neutral | Aug 8, 24 |
| Goldman Sachs | Neutral | Jul 9, 24 |
| Baird | Outperform | May 9, 24 |
| Craig-Hallum | Buy | Apr 10, 24 |
| RBC Capital | Outperform | Feb 23, 24 |